Nyrada Inc – Brain Injury Program GLP Studies Further Update #3

Highlights:
•Completed rat respiratory study provides additional data to support safety and tolerability of Nyrada’s lead Brain Injury drug candidate.
•Study was satisfactorily completed under Good Laboratory Practice (GLP) conditions.
•Nyrada will continue to report on remaining GLP study results and remains on track to commence first in-human Phase I clinical trial for NYR-BI03 in late CY2024.